Tecan Group Ag · SIX:TECN
Tecan — Investor Day (December 2011)
109 slides from Tecan's investor day presentation, Dec 1, 2011
Slide 1: Analyst & Investor Day 2011 Tecan Group AG
December 1, 2011 Analyst & Investor Day 2011 Tecan Group AG
Slide 2: Welcome
December 1, 2011 / p2 / Analyst & Investor Day Tecan Analyst & Investor Day 2011 Willkommen! Welcome! Bienvenue! Benvenuto! Bienvenido! ようこそ 欢迎大家! Приемам ﻼ ً ْﺳﻬ َ ﻼو ً ْأه
Slide 3: Today's Agenda
December 1, 2011 / p3 / Analyst & Investor Day Today’s Agenda • 7:45-8:20 Welcome Coffee • 8:30-12:45 CEO Welcome and Introduction Presentations + Webcast Life Sciences Business Vision & Strategy Strengthening the Core Business LSB Market Expansion and Brand Leverage 10:00-10:15 Break Mass Spectrome
Slide 4: Today's Speakers
December 1, 2011 / p4 / Analyst & Investor Day Today’s Speakers • Welcome and Introduction • Thomas Bachmann, CEO • Life Sciences Business • Frederic Vanderhaegen, Executive VP, Head Life Sciences Business • Wendy Lauber, Product Management, Liquid Handling Robotics and Consumables • Ralf Bartl, Pro
Slide 5: Introduction
Analyst & Investor Day 2011 Introduction Thomas Bachmann, CEO
Slide 6: Tecan's Products, Business Structure and Markets
December 1, 2011 / p6 / Analyst & Investor Day Tecan’s Products, Business Structure and Markets Life Sciences Business Partnering Business • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan • Products sold by partners under brand through own sale
Slide 7: Transition into the new Tecan Group Organization
December 1, 2011 / p7 / Analyst & Investor Day Transition into the new Tecan Group Organization • The new Tecan Group organization was established to support the execution of our growth strategy • Strong market orientation with two distinct businesses • New organization established and lived; transi
Slide 8: Tecan's Business is Supported by Megatrends
December 1, 2011 / p8 / Analyst & Investor Day Tecan’s Business is Supported by Megatrends • Aging population • Increased incidence of diseases such as cancer, diabetes, cardiovascular diseases etc. stimulate research and development of novel drugs • Increasing volume for routine tests and emerging
Slide 9: Strategic Drivers for Sustainable Profitable Growth
December 1, 2011 / p9 / Analyst & Investor Day Strategic Drivers for Sustainable Profitable Growth Life Sciences Partnering Business Business Sales Channel Expanded Project Leverage Pipeline Increased Innovation to Drive Organic Growth High-Value Services & Consumables Geographic Expansion into Grow
Slide 10: Life Sciences Business
Analyst & Investor Day 2011 Life Sciences Business Frederic Vanderhaegen, Executive Vice President Head Life Sciences Business
Slide 11: Agenda
December 1, 2011 / p11 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 11
Slide 12: Life Sciences Business
December 1, 2011 / p12 / Analyst & Investor Day Life Sciences Business Research Laboratories: Academic & commercial discovery and development A leading global provider of automated liquid handling and detection Clinical Laboratories: Biological sample solutions with an added preparation & automation
Slide 13: Life Sciences Business - a global organization
December 1, 2011 / p13 / Analyst & Investor Day Life Sciences Business - a global organization • 33 Application specialists ≙ 45% of total LSB employees • 122 Sales representatives ≙ more than 1/3 of Tecan Group employees • 223 Customer supports
Slide 14: Covering a wide range of research and IVD workflows
December 1, 2011 / p14 / Analyst & Investor Day Covering a wide range of research and IVD workflows Sample Prep Assay Analysis Sequencing, Amplification Gene Gene Sequencing, Molecular Gene Amplification Gene Gene SNP & WGA Molecular Genomics & Purification Cloning Expression SNP & WGA Diagnostics S
Slide 15: Structure of Tecan's current Life Sciences Business
December 1, 2011 / p15 / Analyst & Investor Day Structure of Tecan’s current Life Sciences Business Sales by product segment 9% Biopharma LIHA 37% CD LIHA 23% DETE Service 19% 12% Consumables Sales by geography 12% 7% Europe US 44% Japan Asia Pacific 37%
Slide 16: Why refine our strategy?
December 1, 2011 / p16 / Analyst & Investor Day Why refine our strategy? • Tecan’s current core market is estimated to grow at low single digits and competitive pressure is expected to increase • Tecan wants to outpace market growth • Tecan has successfully focused on developing complex, high-end pl
Slide 17: Strategic priorities
December 1, 2011 / p17 / Analyst & Investor Day Strategic priorities The strategic review process identified 4 areas of focus: Core & Prioritized Adjacencies Sample High-end HP & Australia prep for platform Attana & China Mass Spec Adjacencies in scope: assessed, validated, selected
Slide 18: Agenda
December 1, 2011 / p18 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 18
Slide 19: New high performance plate reader infinite M1000 Pro
December 1, 2011 / p19 / Analyst & Investor Day New high performance plate reader infinite M1000 Pro • Multimode plate readers are one of the fastest growing segments within the lab automation market • The new M1000 Pro multimode reader positions Tecan to exploit this potential and accelerate Instru
Slide 20: Why is Alphascreen important to Tecan?
December 1, 2011 / p20 / Analyst & Investor Day Why is Alphascreen important to Tecan? • Alphascreen is a widely applicable assay (chemistry) platform for drug discovery and applied research applications • Alphascreen assays offer researchers high sensitivity combined with a significantly simplified
Slide 21: Air Displacement Pipetting Technology for the Freedom EVO
December 1, 2011 / p21 / Analyst & Investor Day Air Displacement Pipetting Technology for the Freedom EVO® • Disposable tip only system: Reduced risk of contamination • Higher throughput: Freedom EVO® No washing steps in-between pipetting steps • Lower maintenance costs: No tubing and valves for the
Slide 22: Customized Solutions: flow-cytometry sample preparation
December 1, 2011 / p22 / Analyst & Investor Day Customized Solutions High throughput sample preparation for flow-cytometry • Customer: Pharma project / Japan Freedom EVO® • Industry: Contract Research Laboratory • Revenue: 1.9 Mio. CHF Customized Solutions continue to strengthen our position in high
Slide 23: Customized Solutions: physiology monitoring
December 1, 2011 / p23 / Analyst & Investor Day Customized Solutions Physiology monitoring of microbiological cultures: • Customer: Gov. project / France Freedom EVO® • Industry: Academic Laboratory • Revenue: 470 k CHF Customized Solutions enable unique applications via specialized hardware develop
Slide 24: Sample aliquoting for Biobanking applications
December 1, 2011 / p24 / Analyst & Investor Day Sample aliquoting for Biobanking applications • Biobanking is currently growing driven by population based Biobanks and Pharma biobanks • Tecan well positioned thanks to: Freedom EVO® • Presence in key reference labs such as UK Biobank and the Karolins
Slide 25: The new Tecan Myrius powered by MyControl
The new Tecan Myrius powered by MyControl December 1, November 19,2011 2009/ /p25 p25/ Analyst / Analyst&&Investor InvestorDay Day 30 November, 2011, p 25 Myrius Strategy for Success
Slide 26: Myrius Value Propositions to our Customers
December 1, 2011 / p26 / Analyst & Investor Day Myrius® Value Propositions to our Customers • Simple user interface with integrated touch screen Platforms • Web based technologies for monitoring, providing a walk-away system • Instant pipetting technology on the touch screen allowing real-time actio
Slide 27: Myrius Value Propositions to our Customers
December 1, 2011 / p27 / Analyst & Investor Day Myrius® Value Propositions to our Customers • Trans ROMA allowing the connection of 2 pipetting platforms Platforms • True parallel processing with Trans ROMA • Transport (lateral movements of carriers between chassis) The Myrius Platform fulfills unme
Slide 28: Myrius Value Propositions to our Customers
December 1, 2011 / p28 / Analyst & Investor Day Myrius® Value Propositions to our Customers • Higher Deck capacity compared to Freedom EVO Platforms • Easy integration of 3rd party devices; increases TIG profitability • Modular arm configuration and worktable concept • Integration of detection devic
Slide 29: New Consumables products 2011
December 1, 2011 / p29 / Analyst & Investor Day New Consumables products 2011 25ml trough for maximum Sterile Purity Filtered MCA 384 tips in 5ml Disposable Tip for reagent recovery Disposable Tips additional sizes Liquid Handling Arms Consumables February 2011 May 2011 September 2011 October 2011 L
Slide 30: Nested Disposable Tips for MCA96
December 1, 2011 / p30 / Analyst & Investor Day Nested Disposable Tips for MCA96 • Product launched: January 2009 • Proprietary product developed by and exclusively sold through Tecan • Approximately 100 MCA 96 systems Consumables sold annually MCA96 Disposable Tips sold 60.0 50.0 40.0 mio. tips 30.
Slide 31: New Consumables products: Tecan QC Kit
December 1, 2011 / p31 / Analyst & Investor Day New Consumables products Tecan QC Kit in conjunction with market leader Artel enables new Service business opportunities Consumables Kit components Consumables Microplates Highly Precise Dye solutions Reagents: Color TecanMicroplate Tecan reader Softwa
Slide 32: Customers rely on our Service
December 1, 2011 / p32 / Analyst & Investor Day Customers rely on our Service • Our instruments are integrated in high- value lab processes and workflows preparing assays, performing measure- ments of those assays, and producing Customer Service results • Downtime = lost production time = loss of mo
Slide 33: What is Service?
December 1, 2011 / p33 / Analyst & Investor Day What is „Service“…? • Hardware support • Installation and warranty • Preventive maintenance and repair • Installation- and operational qualification Customer Service • Applications support • Set-up and support during the lifetime of the instrument • Un
Slide 34: Agenda
December 1, 2011 / p34 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 34
Slide 35: Strengths of Tecan Sales and Service Channels
December 1, 2011 / p35 / Analyst & Investor Day Strengths of Tecan Sales and Service Channels • Tecan is global leader in laboratory automation for over 30 years • With an established Sales and Service network in over 50 countries • Following our growth strategy, we are leveraging these strengths by
Slide 36: Direct Digital Titration – Generation of IC50 Curves
December 1, 2011 / p36 / Analyst & Investor Day Direct Digital Titration – Generation of IC50 Curves • The IC50 is the concentration of an inhibitor where the response (or binding) is reduced by half • IC50 curves are used to determine and rank the potency of a series of test compounds • Compounds a
Slide 37: HP Value Proposition
December 1, 2011 / p37 / Analyst & Investor Day HP Value Proposition • Reduce cost by saving on intermediate plates, tips, DMSO and head count • Simplifies the workflow and reduces the amount of time required to prepare a plate Helwett Packard • Preserves precious compound Drug Diluent & Diluent & p
Slide 38: Early Access Customer Testimonials
December 1, 2011 / p38 / Analyst & Investor Day Early Access Customer Testimonials • „For me, it really does revolutionize the way we do drug discovery — taking the process and bringing it back to the researchers is a real tremendous advance,” Helwett Packard - Robert Jordern, SIGA Technologies Sili
Slide 39: Agenda
December 1, 2011 / p39 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 39
Slide 40: China Strategy
December 1, 2011 / p40 / Analyst & Investor Day China Strategy • Fueled by public sector spending and increasing desires for world- class research capabilities, Tecan’s potential market in China is growing at a CAGR of 18% • Tecan used a robust strategic process to identify most attractive segments
Slide 41: Tecan will expand its business in China pursuing a 4 steps plan
December 1, 2011 / p41 / Analyst & Investor Day Tecan will expand its business in China pursuing a 4 steps plan 1 • Establish direct “sales” model for Academia & key Blood Bank Enhance direct sales & Applied Market customers capabilities • Create application support capabilities • Strengthening rela
Slide 42: China go-to-market
December 1, 2011 / p42 / Analyst & Investor Day China go-to-market 1 • Through building up the network Enhance direct of local dealers, Tecan reduces sales capabilities the reliance on single distributor and penetrate the market more effectively at regional level 2 • Shift in sales model drives Enha
Slide 43: Key opinion leaders (KOL) in China
December 1, 2011 / p43 / Analyst & Investor Day KOL refers to an independent expert who is not officially related to Tecan but has a strategic relationship with Tecan to drive customers’ preference 1 Academic Enhance direct Product Leader sales Branding capabilities Influencing Users End User 2 Enha
Slide 44: Agenda
December 1, 2011 / p44 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 44
Slide 45: Mass Spectrometry in the Clinical Laboratory
December 1, 2011 / p45 / Analyst & Investor Day Mass Spectrometry in the Clinical Laboratory Strengths, Applications, Challenges 01‐12‐2011 JMW van den Ouweland, PhD Dept. of Clinical Chemistry Canisius- Canisius-Wilhelmina Hospital Nijmegen, The Netherlands
Slide 46: Overview
December 1, 2011 / p46 / Analyst & Investor Day Overview • brief overview of LC-MS • LC-MS by SWOT analysis • areas of application • drivers of adoption
Slide 47: Historical perspective
December 1, 2011 / p47 / Analyst & Investor Day Historical perspective • immunoassays 1970s • PCR 1980s • mass spectrometry 1990s electrospray ionisation (ESI) (Fenn 1980) Increasing use of LC-MS in clinical laboratories over the last 10-15 years
Slide 48: LC-MS: step by step
December 1, 2011 / p48 / Analyst & Investor Day LC-MS : step by step - dilute & shoot - protein precipitation SAMPLE PREPARATION - liquid-liquid extraction - solid phase extraction - immunoaffinity purification - GC CHROMATOGRAPHY - LC - quadrupole MASS SPECTROMETRY single vs tandem ( sensitivity,
Slide 49: LC-MS by SWOT Analysis
December 1, 2011 / p49 / Analyst & Investor Day LC-MS by SWOT Analysis
Slide 50: Strengths
December 1, 2011 / p50 / Analyst & Investor Day Strengths • high sensitivity • high specificity
Slide 51: Sensitivity & specificity
December 1, 2011 / p51 / Analyst & Investor Day Sensitivity & specificity Herold et al. Clin Chem 2003;49:1250 Rosner et al J Clin Endocrinol Metab 2007;92:405 “LC-MS/MS is the method of choice for the measurement of certain steroid hormones, particularly for those which rely on accurate and specifi
Slide 52: Specificity
December 1, 2011 / p52 / Analyst & Investor Day Specificity Local Cortisol (μg/dL) R2 : 0.58 Average bias 10.13 nmol/L Intensive Care Medicine 2009;35:2151-6 M. Vogeser
Slide 53: Specificity
December 1, 2011 / p53 / Analyst & Investor Day Specificity R2 : 0.58 Average bias 10.13 nmol/L M. Vogeser
Slide 54: Strengths
December 1, 2011 / p54 / Analyst & Investor Day Strengths • high sensitivity • high specificity • near reference methodology in routine setting (isotope-dilution) • high speed of development at low costs of new assays when compared to immunoassays by IVD companies • low costs per sample in terms of
Slide 55: Weaknesses
December 1, 2011 / p55 / Analyst & Investor Day Weaknesses • high instrument costs (≈ €250.000,- for LC-MS/MS) - high test volume needed for cost-effective operation • serial (batch-wise), non random-access operation • need for highly skilled personnel for method development, validation, operation a
Slide 56: Opportunities
December 1, 2011 / p56 / Analyst & Investor Day Opportunities • progress towards more user-friendly instruments (with integration of all components into a single system) • broader availability of CE/IVD approved kits for LC-MS/MS analysis • adoption of MS technology by major IVD companies • quantita
Slide 57: Threats
December 1, 2011 / p57 / Analyst & Investor Day Threats • speed of development of new instruments largely driven by sensitivity needs > hard to keep up with (e.g development of commercially available kits) and requires regular adaptation of routine practice • growing difficulty finding (skilled) tec
Slide 58: Areas of Application in the Clinical Laboratory
December 1, 2011 / p58 / Analyst & Investor Day Areas of Application in the Clinical Laboratory • Metabolic disorders ( e.g. acylcarnitines and amino acids in new born screening) • Therapeutic drug monitoring (e.g. immunosuppressants, antidepressants) • Drugs of abuse and pain-management testing (e.
Slide 59: 25-OH vitamin D measurement by LC-MS
December 1, 2011 / p59 / Analyst & Investor Day 25-OH vitamin D measurement by LC-MS • High prevalence of vitamin D deficiency, with recognition of its importance in skeletal as well as in non-skeletal disease, including autoimmune-, infectious- and cardiovascular disease. • 25OHD testing important
Slide 60: Vitamin D requests
December 1, 2011 / p60 / Analyst & Investor Day Vitamin D requests vitamine D CWZ 8000 7000 6000 5000 number 4000 3000 2000 1000 0 2005 2006 2007 2008 2009 2010 year workload -> sample preparation and analysis time
Slide 61: Sample preparation
December 1, 2011 / p61 / Analyst & Investor Day Sample preparation • on-line SPE Costs (ROI) • semi-automated sample prep • manual 96-wells format • manual manifold
Slide 62: Sample preparation for 25OHD by ILE
December 1, 2011 / p62 / Analyst & Investor Day Sample preparation for 25OHD by ILE ILE = Immobilized Liquid Extraction • rapid and simple sample extraction in 96- well plates • no need for centrifugation, vacuum / positive pressure systems or robotics • simple “pipette & shake” approach
Slide 63: Sample preparation for 25OHD by ILE
December 1, 2011 / p63 / Analyst & Investor Day Sample preparation for 25OHD by ILE • Manual 96-wells SPE format 4 h sample preparation time • Manual 96-wells ILE format 1,5 h sample preparation time 25OHD testing by ILE vs SPE 160 ILE = 1,0 x SPE – 0,799 25OHD (nmol/L) by ILE 140 R= 0,944 (P&B regr
Slide 64: Drivers of adoption of MS in clinical laboratories
December 1, 2011 / p64 / Analyst & Investor Day Drivers of adoption of MS in clinical laboratories • Platform stability & longevity (freezing instrument design) - less revalidation of assays & retraining for users - decreased regulatory compliance burden for vendors - allows expansion of vendor-deve
Slide 65: Drivers of adoption of MS in clinical laboratories continued
December 1, 2011 / p65 / Analyst & Investor Day Drivers of adoption of MS in clinical laboratories continued • Peptide & protein quantification in addition to low molecular weight (LMW) analytes • Laboratory information management system (LIMS) integration • Full support by IVD industry - reagents &
Slide 66: Development of immuno-analysers
December 1, 2011 / p66 / Analyst & Investor Day Development of immuno-analysers 20 years 1981 1988 1993 1999 MS Abbott Abbott TDx Abbott IMx Abbott AxSym ARCHITECT
Slide 67: Thank you for your attention
December 1, 2011 / p67 / Analyst & Investor Day Thank you for your attention
Slide 68: Welcome to the World of Sample Preparation for MS!
December 1, 2011 / p68 / Analyst & Investor Day Welcome to the World of Sample Preparation for MS! • This presentation gives an overview on Tecan’s front-end sample preparation developments for mass spectrometry (the FEMS project) Replica of an early mass spectrometer, Wikipedia
Slide 69: Global Market for Mass Spectrometry
December 1, 2011 / p69 / Analyst & Investor Day Global Market for Mass Spectrometry Market Demand for Instruments and Growth Instrument Demand by Industry CAGR=8.6% Market Demand ($ milions) 2009 Main Mass Spectrometry Techniques in Hospitals & Clinical • Triple Quadrupole: neonatal screening, scree
Slide 70: Popular Clinical Tandem LC-MS application examples
December 1, 2011 / p70 / Analyst & Investor Day Popular Clinical Tandem LC-MS application examples • Endocrinology - Hormones, Steroids, Vitamin D, Catecholamines and Metanephrines • Newborn Screening - Fatty Acid Oxidation Disorders, Amino Acid Profiles, Cystic Fibrosis • Clinical Toxicology, Pain
Slide 71: The key customer problems we are addressing
December 1, 2011 / p71 / Analyst & Investor Day The key customer problems we are addressing • Eliminate the burden of complicated sample preparation • Eliminate laborious and error prone manual workflow • Eliminate the risk of home-brew assays • Improve robustness and reproducibility • Enable standa
Slide 72: 3 phases to pursue the clinical mass spec growth vector
December 1, 2011 / p72 / Analyst & Investor Day 3 phases to pursue the clinical mass spec growth vector Phase 1 Phase 2 Phase 3 LC-MS Vitamin D Kit + potentially Additional Kits Additional Kits Kits additional Kits Automated Sample Prep Extraction Plate Platform (FEMS) Full Service Solution Platform
Slide 73: How will FEMS change the laboratory landscape?
December 1, 2011 / p73 / Analyst & Investor Day How will FEMS change the laboratory landscape? Vision Bring MS based testing to the same level of ease of use and performance as immunoassays by providing a panel of sample preparation solutions for clinical workflows. Realization • Automation of workf
Slide 74: Phase 1: Faster market entry of the FEMS Project
December 1, 2011 / p74 / Analyst & Investor Day Phase1: Faster market entry of the FEMS Project • In addition to our dedicated sample preparation solution, we have decided to also develop a DWP based solution for Vitamin D isolation • Earlier market entry • Get market awareness • Proof of principle
Slide 75: The Vitamin D on DWP product for launch
December 1, 2011 / p75 / Analyst & Investor Day The Vitamin D on DWP product for launch • Extraction plate with reagents to isolate Vitamin D from serum or plasma • 96 and 576 tests per kit
Slide 76: Phase 2: Dedicated sample preparation
December 1, 2011 / p76 / Analyst & Investor Day Phase 2: Dedicated sample preparation • Automate clinical sample preparation of small molecules • LC-MS front-end • Full sample/reagent tracking • Highest data comparability and reproducibility • Enable use by low-skilled personnel • Speed up sample pr
Slide 77: Pre-Launch Activities
December 1, 2011 / p77 / Analyst & Investor Day Pre-Launch Activities Activity •Symposium/Exhibition •6 Beta-sites executed •Launch Q1 2012 • Key features • High reproducibility • Excellent protein removal • Automation friendly • Fast Feedback • High interest in the technology • Speed and simplicity
Slide 78: Summary
December 1, 2011 / p78 / Analyst & Investor Day Summary • Outstanding consumable-driven product concept • Builds on Tecan strengths in sample preparation, liquid handling expertise and the strong Tecan brand • Founded on an exciting proprietary technology • Significant high margin business potential
Slide 79: Agenda
December 1, 2011 / p79 / Analyst & Investor Day Agenda Vision and Strategy Strengthening the core business Market expansion Sample Prep for Mass Spec and brand leverage as a new innovation focus 79
Slide 80: 4 Strategic priorities for Life Sciences Business
December 1, 2011 / p80 / Analyst & Investor Day 4 Strategic priorities for Life Sciences Business We identified 4 priorities that balance and leverage existing product portfolio and sales channels Goals: Prioritize a major • Double digit sales CAGR growth vector by developing the MS • EBIT improveme
Slide 81: Partnering Business Update
Analyst & Investor Day 2011 Partnering Business Update Dr. Bernhard Grob, Executive Vice President Head of Partnering Business
Slide 82: Contents
December 1, 2011 / p82 / Analyst & Investor Day Contents • Tecan’s Current Partnering Business • Update on various OEM Projects • Project Acquisition Pipeline
Slide 83: Tecan's Growing OEM Business
December 1, 2011 / p83 / Analyst & Investor Day Tecan’s Growing OEM Business Partnering Business sales Partnering Business as a % of total sales 160 140 43.7% H1 2011 •Total sales for all periods are from continuing operations only 120 CAGR: 10.5% CAGR: 14.4% 100 80 60 37.8% CHF (mio) 40 20 2010 0 2
Slide 84: Structure of Partnering Business
December 1, 2011 / p84 / Analyst & Investor Day Structure of Partnering Business Sales by Product Group 9% Liquid Handling 7% Components 55% Detection 29% R&D Funding Sales by Product Class 9% Systems / Instruments 6% Components 17% 46% Service/Spare Parts Plastic Consumables 22% R&D Funding
Slide 85: Tecan's Broad OEM Offering
December 1, 2011 / p85 / Analyst & Investor Day Tecan’s Broad OEM Offering Integrated Solutions • Concepts developed by Tecan and showcased to potential partners • Integrating instrument, plastic consumables and enabling reagents Dedicated Solutions Plastic Consumables Customer Service & P14 P16 Spa
Slide 86: Contents
December 1, 2011 / p86 / Analyst & Investor Day Contents • Tecan’s Current Partnering Business • Update on various OEM Projects • Project Acquisition Pipeline
Slide 87: P14: Major OEM Agreement
December 1, 2011 / p87 / Analyst & Investor Day P14: Major OEM Agreement • Contract signed in November 2010 • Tecan to develop and supply next generation blood-banking instrument • Builds upon established OEM partnership with a global leader • Program in advanced development stage • Addresses variou
Slide 88: P16: Major Agreement with New OEM Customer
December 1, 2011 / p88 / Analyst & Investor Day P16: Major Agreement with New OEM Customer • P16 program - agreement with new OEM customer, a global leader in a fast growing field of diagnostics, signed in May 2011 • Tecan to develop and supply a next generation dedicated diagnostics instrument • Sa
Slide 89: Enigma: Point-of-care Molecular Diagnostics
December 1, 2011 / p89 / Analyst & Investor Day Enigma: Point-of-care Molecular Diagnostics • Tecan will industrialize and deliver commercially manufactured instruments for GSK Europe and Enigma Diagnostic’s global market supplies • Enigma ML instrument delivers fully-automated results from swab sam
Slide 90: Expansion of Hologic's Molecular Laboratory Solutions
December 1, 2011 / p90 / Analyst & Investor Day Expansion of Hologic’s Molecular Laboratory Solutions Sample Extraction HPV Total Solution New: DNA Extraction 24, 48 or 96 samples Various Molecular Tests Launch of Cervista MTA expands Hologic’s portfolio and allows it to tap into the lower throu
Slide 91: Signed OEM Development & Supply Contracts
December 1, 2011 / p91 / Analyst & Investor Day Signed OEM Development & Supply Contracts 2010 2011 2012 2013 Liquid Handling Solutions Supply of 9 instruments Under development / recently launched: DNA Extractor (MDx) High Throughput HTA Mid Throughput MTA (PoC MDx) Enigma ML (MDx) Configuration 1
Slide 92: Our OEM Instrument Partners
December 1, 2011 / p92 / Analyst & Investor Day Our OEM Instrument Partners Liquid Handling Solutions Detection Instruments
Slide 93: Contents
December 1, 2011 / p93 / Analyst & Investor Day Contents • Tecan’s Current Partnering Business • Update on various OEM Projects • Project Acquisition Pipeline
Slide 94: Project Acquisition Pipeline for OEM Systems
December 1, 2011 / p94 / Analyst & Investor Day Project Acquisition Pipeline for OEM Systems Number of Pipeline Projects • 3 new agreements signed since By Product Group November 2010 6 Liquid Handling 13 • Currently, an additional 3 new agreements or amendments to existing agreements for Detection
Slide 95: Innovation at Tecan
Analyst & Investor Day 2011 Innovation at Tecan Dr. Martin Brusdeilins, Executive Vice President Head of Development & Operations and CSO
Slide 96: Innovation at Tecan – The New Organization
December 1, 2011 / p96 / Analyst & Investor Day Innovation at Tecan – The New Organization Combines Research, Development and Operations Life Sciences Partnering Science & Technology Business Business Focused on all Focused on all Innovation end-customer OEM activities & activities Incubation Develo
Slide 97: New Strategic Areas Require a Solid Road Map Approach
December 1, 2011 / p97 / Analyst & Investor Day New Strategic Areas Require a Solid Road Map Approach Product Line Strategy Future Product Portfolio Product Roadmap Platform Strategy Technology Gap Analysis Current Technology Technology Portfolio Roadmap
Slide 98: Strategy Determines the Product Road Map… Example: FEMS
December 1, 2011 / p98 / Analyst & Investor Day Strategy Determines the Product Road Map… Example: FEMS Instruments and Automation Automated For Plate Components Sample Prep GC & LC Full Service Solution Valves FEMS Reagents VitD Plate Analyte Panel 1 Analyte Panel 4 3rd party Analyte Panel 2 Analyt
Slide 99: The Product Road Map Determines the Platform Design
December 1, 2011 / p99 / Analyst & Investor Day The Product Road Map Determines the Platform Design Enabling Technologies ET1 ET1 ET1 ET1 ET1 ET1 Platform Collection of plug-and-play fully verified & validated modules to be used in products Products Product1 Product2 Product3 Product4 A platform app
Slide 100: Example - Liquid Handling Platform
December 1, 2011 / p100 / Analyst & Investor Day Example - Liquid Handling Platform MCA MCA Detec- Enabling Technologies PMP 96 384 AirLiHa tor PosID Platform Collection of plug-and-play fully verified & validated modules to be used in products Products EVO 75 EVO 100 EVO 150 EVO 200 EVOLyzer
Slide 101: Strategic Alignment of Technology Projects
December 1, 2011 / p101 / Analyst & Investor Day Strategic Alignment of Technology Projects Will Cover the Following Segments Corporate Strategy LSB Strategy PB Strategy Core Business
Slide 102: Seamless R&D and Operations Strategy
December 1, 2011 / p102 / Analyst & Investor Day Seamless R&D and Operations Strategy • Product Road Map(s) to educate Product Platform design(s) • Mature technologies to enter development portfolio • Development of plug & play modules to feed product platforms • Allowing for continuous stream of de
Slide 103: Summary and Conclusion
Analyst & Investor Day 2011 Summary and Conclusion Thomas Bachmann, CEO
Slide 104: Market Dynamics
December 1, 2011 / p104 / Analyst & Investor Day Market Dynamics Tailwind Headwind • Megatrends are intact • Financial crisis and increased recessionary fears • Strong demand in Emerging Markets • Austerity measures in various countries impacting • Continued solid demand in investments in research a
Slide 105: Tecan's Diversification Provides a Solid Basis
December 1, 2011 / p105 / Analyst & Investor Day Tecan‘s Diversification Provides a Solid Basis Sales by region Sales by customer segments 4% 12% 12% 37% 14% 58% 47% 16% North America Asia Diagnostics Pharma Europe Other Biotech Academia Sales by distribution channels Sales by product groups 8% 38%
Slide 106: Accelerating Profitable Growth
December 1, 2011 / p106 / Analyst & Investor Day Accelerating Profitable Growth * Sales 2007-2010 excluding Sample Management Sales growth in local currencies* 12 10 8.4 8 6 4 2.7 Outlook 2.1 Guidance 2 -0.6 0 2007 2008 2009 2010 2011e 2012e 2013e -2 • Launch of Air Displacement technology, • Supply
Slide 107: Confirming Outlook for Full Year 2011
December 1, 2011 / p107 / Analyst & Investor Day Confirming Outlook for Full Year 2011 Sales FY 2011 Profitability FY 2011 As of March 10, 2011 EBIT Margin of 12-13% Mid-single-digit sales growth in Based on average FX rates of: local currencies 1.30 EUR/CHF and 1.00 USD/CHF Updated guidance as of A
Slide 108: Summary and Conclusion
December 1, 2011 / p108 / Analyst & Investor Day Summary and Conclusion • Megatrends are supporting our business • Major development projects underway • Several key product launches in 2012 and 2013 • Well positioned to capture multiple growth opportunities • Life Sciences Business and Partnering Bu
Slide 109: Safe Harbor Statement
Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions of the future and constitute no guarantee whatsoever of future performances. They are subject to risks and uncertainties including, but not limited to, future global economic conditions, excha